At a glance
ClinicalIndex Comparison RecordN/ACompleted· 61 enrolled
Drug / intervention
Coenzyme Q10 +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind Study
In Brief
A clinical study evaluating Coenzyme Q10 and Placebo for Progressive Supranuclear Palsy. Completed, enrolled 61 participants across 3 sites.
Detailed Summary
The clinical syndrome of PSP responds poorly to all available forms of therapy used in Parkinson's Disease (PD). Currently, no effective treatment exists. Coenzyme Q10 in high doses has been shown to be a beneficial therapy in PD and might possibly be a beneficial therapy for PSP. This study will compare the efficacy, safety and tolerability of Coenzyme Q10 versus placebo in patients with atypical parkinsonian syndrome, progressive supranuclear palsy (PSP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgressive Supranuclear Palsy
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2006
First PostedOct 2006
Primary CompletionSep 2013
Study CompletionJan 2015
TodayJul 2026
First PostedOct 2, 2006
Enrollment StartSep 1, 2006
Primary CompletionSep 1, 2013
Study CompletionJan 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7 yearsPosted 19.8 years ago
Interventions
Coenzyme Q10dietary
active drug
Placeboother
Placebo